Acebutolol effects on lipid profile.
Author(s): Schnaper HW.
Affiliation(s): University of Alabama, Center for Aging, Birmingham 35294.
Publication date & source: 1990, Am J Cardiol. , 66(9):49C-54C
The relation between lipid profile and the incidence of coronary artery disease
has been confirmed by the results of epidemiologic and intervention studies.
Among antihypertensive agents, beta blockers, particularly those without
intrinsic sympathomimetic activity (ISA), are generally reported to have negative
effects on lipids, which may increase the risk of coronary artery disease. The
ongoing Treatment of Mild Hypertension Study, now in its third year, has
evaluated 847 patients to date with regard to lipid profile. Additional end
points measured in this multicenter, randomized, controlled, double-blind study
include blood pressure reduction and target organ deterioration. During the
trial, all patients received nutritional and behavioral counselling to modify
their diet, exercise habits and alcohol and sodium consumption to control their
hypertension by nonpharmacologic means. In addition, some patients were
randomized to receive low doses of 1 of the 5 classes of antihypertensive
medication: acebutolol, a beta blocker with ISA (n = 124); amlodipine, a calcium
channel blocker (n = 122); chlorthalidone, a diuretic (n = 125); doxazosin, an
alpha blocker (n = 128); enalapril, an angiotensin-converting enzyme inhibitor (n
= 127) or placebo (n = 221). At 1 year, acebutolol showed a statistically
significant (p less than 0.001) decrease in total cholesterol (-12.7 mg/dl)
compared with placebo (-5.2 mg/dl) and with chlorthalidone (1.0 mg/dl); a
significant (p less than 0.001) decrease in low-density lipoprotein cholesterol
(-6.0 mg/dl) compared with placebo (+0.7 mg/dl) and with chlorthalidone (+8.0
mg/dl) and no change in high-density lipoprotein cholesterol (-0.4 mg/dl).
Erratum in
Am J Cardiol 1990 Dec 1;66(19):A8.
|